An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease

NCT ID: NCT01134367

Last Updated: 2011-07-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-05-31

Study Completion Date

2010-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to examine patient's perspective of symptom control and impact of gastroesophageal reflux disease (GERD) on daily life.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

GERD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Patients with GERD

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with gastroesophageal reflux disease -GERD (disease duration ≤3 years or newly diagnosed) that are currently not treated with a proton pump inhibitor, for whom the general practitioner (GP) has previously decided to initiate or change the tre
* Patients should be treated for GERD according to current practice (National guideline for treatment of dyspepsia in GP setting)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Miodrag Krstić, Prof.Dr

Role: PRINCIPAL_INVESTIGATOR

Institute for Gastroenterology, Clinical Center of Serbia, Belgrade

Dragomir Damjanov, Prof. Dr

Role: PRINCIPAL_INVESTIGATOR

Clinic for Internal Diseases, Clinical Center of Vojvodina, Novi Sad

Aleksandar Nagorni, Prof. Dr

Role: PRINCIPAL_INVESTIGATOR

Clinic for Internal Diseases- Gastroenterology Dept, Clinical Center Nis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Belgrade, , Serbia

Site Status

Research Site

Leskovac, , Serbia

Site Status

Research Site

Niš, , Serbia

Site Status

Research Site

Novi Sad, , Serbia

Site Status

Research Site

Pančevo, , Serbia

Site Status

Research Site

Subotica, , Serbia

Site Status

Research Site

Zrenjanin, , Serbia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Serbia

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-GRS-DUM-2010/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Symptom Adapted Therapy in GERD Patients
NCT00343161 COMPLETED PHASE4